| 1SPJ | A: | STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE |
| 1W0Y | H: | TF7A_3771 COMPLEX |
| 1W2K | H: | TF7A_4380 COMPLEX |
| 1W7X | H: | FACTOR7 - 413 COMPLEX |
| 1W8B | H: | FACTOR7 - 413 COMPLEX |
| 1WQV | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE |
| 1WSS | H: | HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4 |
| 1WTG | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE |
| 1WU1 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE |
| 1WUN | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE |
| 1WV7 | H: | HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE |
| 1Z6E | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389) |
| 1Z71 | A: | THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE |
| 1ZGI | A: | THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21 |
| 1ZGV | A: | THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2 |
| 1ZRB | A: | THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B |
| 2AER | H: | CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX. |
| 2ANW | A: | EXPRESSION, CRYSTALLIZATION AND THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS |
| 2ANY | A: | EXPRESSION, CRYSTALLIZATION AND THE THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS |
| 2BDY | A: | THROMBIN IN COMPLEX WITH INHIBITOR |
| 2BMG | B: | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50 |
| 2BOH | B: | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND "1" |
| 2BOK | A: | FACTOR XA - CATION |
| 2BQ6 | B: | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21 |
| 2BQ7 | B: | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43 |
| 2BQW | B: | CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45 |
| 2BZ6 | H: | ORALLY AVAILABLE FACTOR7A INHIBITOR |
| 2CJI | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2D1J | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5-CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[3,2-B]PYRIDINE N-OXIDE |
| 2EC9 | H: | CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA , SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607 |
| 2EI6 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
| 2EI7 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL)CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
| 2EI8 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S,2R,4S)-N1-[(5-CHLOROINDOL-2-YL)CARBONYL]-4-(N,N-DIMETHYLCARBAMOYL)-N2-[(5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDIN-2-YL) CARBONYL]-1,2-CYCLOHEXANEDIAMINE |
| 2F9N | A:; B:; C:; D: | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN |
| 2F9O | A:; B:; C:; D: | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G |
| 2F9P | A:; B:; C:; D: | CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN |
| 2FZZ | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-6-(2'-(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1,4,5,6-TETRAHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE |
| 2G00 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2'-((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3-(TRIFLUOROMETHYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-1-YL)BENZAMIDE |
| 2H9E | H: | CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX |
| 2J2U | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2J34 | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2J38 | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2J4I | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2J94 | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2J95 | A: | CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX |
| 2JKH | A: | FACTOR XA - CATION INHIBITOR COMPLEX |
| 2O8T | A: | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS |
| 2O8U | A: | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS |
| 2O8W | A: | CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS |
| 2P16 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE |
| 2P3F | H: | CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX |
| 2P3T | B: | CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2-CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2-YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE |
| 2P3U | B: | CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663} |
| 2P93 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE |
| 2P94 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H-INDOLE-6-CARBOXAMIDE |
| 2P95 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE |
| 2Q1J | A: | THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS |
| 2RG3 | A: | COVALENT COMPLEX STRUCTURE OF ELASTASE |
| 2UWL | A: | SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA |
| 2UWO | A: | SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA |
| 2UWP | A: | FACTOR XA INHIBITOR COMPLEX |
| 2VH0 | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS |
| 2VH6 | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS |
| 2VIN | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VIO | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VIP | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VIQ | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VIV | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VIW | A: | FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 2VVC | A:; B: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2VVU | A: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2VVV | A: | AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR |
| 2VWL | A: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2VWM | A:; B: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2VWN | A: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2VWO | A: | AMINOPYRROLIDINE FACTOR XA INHIBITOR |
| 2W26 | A: | FACTOR XA IN COMPLEX WITH BAY59-7939 |
| 2W3I | A: | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2 |
| 2W3K | A: | CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1 |
| 2WPH | S: | FACTOR IXA SUPERACTIVE TRIPLE MUTANT |
| 2WPJ | S: | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED |
| 2WPK | S: | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED |
| 2WPL | S: | FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED |
| 2WPM | S: | FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED |
| 2WYG | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS |
| 2WYJ | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS |
| 2XBV | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XBW | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XBX | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XBY | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XC0 | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XC4 | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2XC5 | A: | FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR |
| 2Y5F | A: | FACTOR XA - CATION INHIBITOR COMPLEX |
| 2Y5G | A: | FACTOR XA - CATION INHIBITOR COMPLEX |
| 2Y5H | A: | FACTOR XA - CATION INHIBITOR COMPLEX |
| 2Y7X | A: | THE DISCOVERY OF POTENT AND LONG-ACTING ORAL FACTOR XA INHIBITORS WITH TETRAHYDROISOQUINOLINE AND BENZAZEPINE P4 MOTIFS |
| 2Y7Z | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS |
| 2Y80 | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS |
| 2Y81 | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS |
| 2Y82 | A: | STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS |
| 2Z7F | E: | CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN NEUTROPHIL ELASTASE WITH 1/2SLPI |
| 2ZCH | P: | CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY |
| 3C1K | A: | CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR 15 |
| 3CEN | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2-PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)-PYRIDINYL)BENZAMIDE |
| 3CS7 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)-6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
| 3ENS | B:; D: | CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3-CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2-PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE |
| 3FFG | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2'-((3-HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4, 5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
| 3HPT | B: | CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2-METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE |
| 3IIT | A: | FACTOR XA IN COMPLEX WITH A CIS-1,2-DIAMINOCYCLOHEXANE DERIVATIVE |
| 3K9X | B: | X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE |
| 3KQB | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE |
| 3KQC | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
| 3KQD | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
| 3KQE | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE |
| 3M36 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[3-(AMINOMETHYL) PHENYL]-N-[3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC423) |
| 3M37 | A: | FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[2-(AMINOMETHYL) PHENYL]-N-(3-FLUORO-2'-SULFAMOYLBIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC602) |
| 3PB1 | E: | CRYSTAL STRUCTURE OF A MICHAELIS COMPLEX BETWEEN PLASMINOGEN ACTIVATOR INHIBITOR-1 AND UROKINASE-TYPE PLASMINOGEN ACTIVATOR |
| 3Q3K | A: | FACTOR XA IN COMPLEX WITH A PHENYLENEDIAMINE DERIVATIVE |
| 3Q76 | A:; B: | STRUCTURE OF HUMAN NEUTROPHIL ELASTASE (UNCOMPLEXED) |
| 3Q77 | A: | STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR |
| 3SQH | E: | CRYSTAL STRUCTURE OF PRETHROMBIN-2 MUTANT S195A IN THE THE OPEN FORM |
| 3TJU | A: | CRYSTAL STRUCTURE OF HUMAN GRANZYME H WITH AN INHIBITOR |
| 3TJV | A: | CRYSTAL STRUCTURE OF HUMAN GRANZYME H WITH A PEPTIDYL SUBSTRATE |
| 3TK5 | A: | FACTOR XA IN COMPLEX WITH D102-4380 |
| 3TK6 | A: | FACTOR XA IN COMPLEX WITH D46-5241 |
| 3TK9 | A: | CRYSTAL STRUCTURE OF HUMAN GRANZYME H |
| 3VFE | A: | VIRTUAL SCREENING AND X-RAY CRYSTALLOGRAPHY FOR HUMAN KALLIKREIN 6 INHIBITORS WITH AN AMIDINOTHIOPHENE P1 GROUP |
| 4A7I | B: | FACTOR XA IN COMPLEX WITH A POTENT 2-AMINO-ETHANE SULFONAMIDE INHIBITOR |
| 4D8N | A: | HUMAN KALLIKREIN 6 INHIBITORS WITH A PARA-AMIDOBENZYLANMINE P1 GROUP CARRY A HIGH BINDING EFFICIENCY |
| 4DGJ | A:; B:; C:; D: | STRUCTURE OF A HUMAN ENTEROPEPTIDASE LIGHT CHAIN VARIANT |
| 4GAW | A:; B:; C:; D:; E:; F:; G:; H:; I:; J:; K:; L: | CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H |
)
)